Skip to main content

Table 1 Patient characteristics

From: A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors

Characteristic

Patients, n (%)

Patients enrolled

16

Age (yrs)

 Median

49

 Range

30–67

Sex

 Male

7 (44)

 Female

9 (56)

ECOG performance status

 0

3 (19)

 1

13 (81)

Tumor type

 Breast cancer

4 (25)

 Pancreatic cancer

5 (31)

 gastric cancer

4 (25)

 Other

3 (19)

Previous treatment

 Surgery

14 (88)

 Radiotherapy

9 (56)

 Chemotherapy

16 (100)

  1. Abbreviation: ECOG Eastern Cooperative Oncology Group